СОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ ТАКСОТЕРА® ПРИ ДИССЕМИНИРОВАННОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1994-4098-2008-0-1-41-44
Аннотация
СОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ ТАКСОТЕРА® ПРИ ДИССЕМИНИРОВАННОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ
Об авторах
К. В. ЮрашкоРоссия
В. А. Горбунова
Россия
В. М. Самойленко
Россия
Список литературы
1. Fisher B., Osborn K., Margolese R. et al. Neoplasms of the breast. Cancer medi- cine. 3-d edition. Ed. By J. Holland et al.; 1993. p. 1706—74.
2. Jones S.E., Erban J., Overmoyer B. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542—51.
3. Harvey V., Mouridsen H., Semiglazov V. et. al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. J Clin Oncol 2006;24(31):4963—70.
4. Chan S., Friedricks K., Noel D. et al. Prostective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. TAX 303. J Clin Oncol 1999;17:2341—54.
5. Nabholtz J.M., Senn H.J., Bezwoda W.R. et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblas- tine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413—24.
6. O'Shaughnessy J., Miles D., Vukelja S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812—23.
7. Nabholtz J.M., Falkson C., Campos D. et al. Docetaxel and doxorubicin com- pared with doxorubicin and cyclophos- phamide as first-line chemotherapy for metastatic breast cancer. Results of a ran-
8. domized, multicenter, phase III trial. J Clin Oncol 2003;21:968—75.
9. Bontenbal M., Creemers G.J., Braun H.J. et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer. Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081—8.
10. Bonneterre J., Dieras V., Tubiana-Hulin M. et al. Phase II multi- centre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004;91:1466—71.
Рецензия
Для цитирования:
Юрашко К.В., Горбунова В.А., Самойленко В.М. СОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ ТАКСОТЕРА® ПРИ ДИССЕМИНИРОВАННОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ. Опухоли женской репродуктивной системы. 2008;(1):41-44. https://doi.org/10.17650/1994-4098-2008-0-1-41-44